SHOLO®. PDE4 short form inhibitors

Sholo®  – PDE4 short form inhibitors

Mironid’s ShoLo® inhibitor program for inflammatory diseases has developed novel PDE4 short form selective inhibitors to focus on regulating the disease-relevant PDE4 family members, without having an equivalent inhibitory effect on the long form isoforms, which can lead to adverse side effects. This selectivity allows Mironid to generate drug-like molecules that should have improved clinical efficacy and reduced side effect profiles compared to the current generation of pan-PDE4 inhibitors, which inhibit all PDE4 enzymes.

An ambitious, vibrant, growing, customer-centric company

get in touch